The New and the Old: Platform Cross-Validation of Immunoaffinity MASS Spectrometry versus ELISA for PromarkerD, a Predictive Test for Diabetic Kidney Disease

PromarkerD is a proteomics derived test for predicting diabetic kidney disease that measures the concentrations of three plasma protein biomarkers, APOA4, CD5L and IBP3. Antibodies against these proteins were developed and applied to a multiplexed immunoaffinity capture mass spectrometry assay. In p...

Descripción completa

Detalles Bibliográficos
Autores principales: Bringans, Scott, Peters, Kirsten, Casey, Tammy, Ito, Jason, Lipscombe, Richard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7709118/
https://www.ncbi.nlm.nih.gov/pubmed/33126588
http://dx.doi.org/10.3390/proteomes8040031
_version_ 1783617684940783616
author Bringans, Scott
Peters, Kirsten
Casey, Tammy
Ito, Jason
Lipscombe, Richard
author_facet Bringans, Scott
Peters, Kirsten
Casey, Tammy
Ito, Jason
Lipscombe, Richard
author_sort Bringans, Scott
collection PubMed
description PromarkerD is a proteomics derived test for predicting diabetic kidney disease that measures the concentrations of three plasma protein biomarkers, APOA4, CD5L and IBP3. Antibodies against these proteins were developed and applied to a multiplexed immunoaffinity capture mass spectrometry assay. In parallel, and facilitating current clinical laboratory workflows, a standard ELISA was also developed to measure each protein. The performance characteristics of the two technology platforms were compared using a cohort of 100 samples, with PromarkerD test scores demonstrating a high correlation (R = 0.97). These technologies illustrate the potential for large scale, high throughput clinical applications of proteomics now and into the future.
format Online
Article
Text
id pubmed-7709118
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-77091182020-12-03 The New and the Old: Platform Cross-Validation of Immunoaffinity MASS Spectrometry versus ELISA for PromarkerD, a Predictive Test for Diabetic Kidney Disease Bringans, Scott Peters, Kirsten Casey, Tammy Ito, Jason Lipscombe, Richard Proteomes Article PromarkerD is a proteomics derived test for predicting diabetic kidney disease that measures the concentrations of three plasma protein biomarkers, APOA4, CD5L and IBP3. Antibodies against these proteins were developed and applied to a multiplexed immunoaffinity capture mass spectrometry assay. In parallel, and facilitating current clinical laboratory workflows, a standard ELISA was also developed to measure each protein. The performance characteristics of the two technology platforms were compared using a cohort of 100 samples, with PromarkerD test scores demonstrating a high correlation (R = 0.97). These technologies illustrate the potential for large scale, high throughput clinical applications of proteomics now and into the future. MDPI 2020-10-28 /pmc/articles/PMC7709118/ /pubmed/33126588 http://dx.doi.org/10.3390/proteomes8040031 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Bringans, Scott
Peters, Kirsten
Casey, Tammy
Ito, Jason
Lipscombe, Richard
The New and the Old: Platform Cross-Validation of Immunoaffinity MASS Spectrometry versus ELISA for PromarkerD, a Predictive Test for Diabetic Kidney Disease
title The New and the Old: Platform Cross-Validation of Immunoaffinity MASS Spectrometry versus ELISA for PromarkerD, a Predictive Test for Diabetic Kidney Disease
title_full The New and the Old: Platform Cross-Validation of Immunoaffinity MASS Spectrometry versus ELISA for PromarkerD, a Predictive Test for Diabetic Kidney Disease
title_fullStr The New and the Old: Platform Cross-Validation of Immunoaffinity MASS Spectrometry versus ELISA for PromarkerD, a Predictive Test for Diabetic Kidney Disease
title_full_unstemmed The New and the Old: Platform Cross-Validation of Immunoaffinity MASS Spectrometry versus ELISA for PromarkerD, a Predictive Test for Diabetic Kidney Disease
title_short The New and the Old: Platform Cross-Validation of Immunoaffinity MASS Spectrometry versus ELISA for PromarkerD, a Predictive Test for Diabetic Kidney Disease
title_sort new and the old: platform cross-validation of immunoaffinity mass spectrometry versus elisa for promarkerd, a predictive test for diabetic kidney disease
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7709118/
https://www.ncbi.nlm.nih.gov/pubmed/33126588
http://dx.doi.org/10.3390/proteomes8040031
work_keys_str_mv AT bringansscott thenewandtheoldplatformcrossvalidationofimmunoaffinitymassspectrometryversuselisaforpromarkerdapredictivetestfordiabetickidneydisease
AT peterskirsten thenewandtheoldplatformcrossvalidationofimmunoaffinitymassspectrometryversuselisaforpromarkerdapredictivetestfordiabetickidneydisease
AT caseytammy thenewandtheoldplatformcrossvalidationofimmunoaffinitymassspectrometryversuselisaforpromarkerdapredictivetestfordiabetickidneydisease
AT itojason thenewandtheoldplatformcrossvalidationofimmunoaffinitymassspectrometryversuselisaforpromarkerdapredictivetestfordiabetickidneydisease
AT lipscomberichard thenewandtheoldplatformcrossvalidationofimmunoaffinitymassspectrometryversuselisaforpromarkerdapredictivetestfordiabetickidneydisease
AT bringansscott newandtheoldplatformcrossvalidationofimmunoaffinitymassspectrometryversuselisaforpromarkerdapredictivetestfordiabetickidneydisease
AT peterskirsten newandtheoldplatformcrossvalidationofimmunoaffinitymassspectrometryversuselisaforpromarkerdapredictivetestfordiabetickidneydisease
AT caseytammy newandtheoldplatformcrossvalidationofimmunoaffinitymassspectrometryversuselisaforpromarkerdapredictivetestfordiabetickidneydisease
AT itojason newandtheoldplatformcrossvalidationofimmunoaffinitymassspectrometryversuselisaforpromarkerdapredictivetestfordiabetickidneydisease
AT lipscomberichard newandtheoldplatformcrossvalidationofimmunoaffinitymassspectrometryversuselisaforpromarkerdapredictivetestfordiabetickidneydisease

Ejemplares similares